Vitality Biopharma secures $5M equity line; S-1 effective, DTC eligible

RANGE IMPACT, INC.

SEC declared Form S-1 effective on Sept 2, 2021, registering shares for resale by Triton Funds under a $5M equity line.
Proceeds from the equity line will fund pre-clinical studies of lead prodrug VBX-100 and general corporate purposes.
VBX-100, a glycosylated cannabinoid, received FDA Orphan Drug Designation for pediatric ulcerative colitis.
Common shares deemed DTC eligible effective July 1, 2021, enabling electronic clearing and settlement.
Only Triton Funds LP may use the prospectus to resell shares under the registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.